Nivolumab Immunotherapy–Related Skin Reactions Detected on 18F-FDG PET/CT in Renal Cell Cancer

alexandrossfakianakis shared this article with you from Inoreader Nivolumab Immunotherapy–Related Skin Reactions Detected on 18F-FDG PET/CT in Renal Cell Cancer Via Clinical Nuclear Medicine - Published Ahead-of-Print Nivolumab, a fully human immunoglobulin G4 anti–programmed cell death 1 antibody, provides a novel therapy option for patients with metastatic cancers. Immunotherapy agents have been associated with immune-related adverse events (irAEs), which may be detected on 18F-FDG PET/CT. Cutaneous toxicities are one of the most common irAEs in the form of maculopapular rash (eczema-like spongiotic dermatitis) and pruritus. These irAEs may lead to false-positive findings on PET/CT done during the treatment. One should be aware of the potential irAEs while interpreting PET/CT to avoid misinterpretation. View on the web Inoreader. Take back control of your news feed. Follow us on Twitter and Facebook.